Compare FOFO & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FOFO | NCEL |
|---|---|---|
| Founded | 2017 | 2008 |
| Country | Hong Kong | Switzerland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.2M | 19.4M |
| IPO Year | 2025 | 2019 |
| Metric | FOFO | NCEL |
|---|---|---|
| Price | $2.01 | $2.66 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 194.4K | 5.7K |
| Earning Date | 12-04-2026 | 09-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.09 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.70 | $1.83 |
| 52 Week High | $14.93 | $5.12 |
| Indicator | FOFO | NCEL |
|---|---|---|
| Relative Strength Index (RSI) | 45.90 | 40.88 |
| Support Level | $1.76 | $1.95 |
| Resistance Level | $2.68 | $3.32 |
| Average True Range (ATR) | 0.19 | 0.33 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 28.57 | 20.68 |
Hang Feng Technology Innovation Co Ltd is committed to providing comprehensive corporate management consulting and asset management services, tailored to address the specific needs of each client. Its goal is to empower its clients to design, implement, and achieve their business and investment objectives. Its business consists of two main business lines: (i) corporate management consulting services and (ii) asset management services. The corporate management consulting services include Management consulting and Regulatory compliance and governance consulting, and the asset management services, including fund subscription and fund management services.
NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.